Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback